AIM ImmunoTech Inc. 8-K

What Happened AIM ImmunoTech Inc. (AIM) announced on June 9, 2026 that its Board approved an amendment to the company’s Amended and Restated Bylaws. The Amendment changes the vote counting rule for proposals other than the election of directors so that such proposals are approved by the affirmative vote of a majority of the votes cast on the proposal (counting only votes for or against, and excluding abstentions and broker non‑votes).

Key Details

• Amendment effective date: June 9, 2026; approved by the Board of Directors.
• New voting standard: approval requires the affirmative vote of a majority of votes cast (only for or against votes counted).
• Prior standard: approval required a majority in voting power of shares present in person or by proxy and entitled to vote on the matter.
• The change applies to all proposals other than the election of directors; exhibit (Amendment) filed as Exhibit 3.1 to the 8-K.

Why It Matters The company changed how shareholder support is measured for non‑director proposals by excluding abstentions and broker non‑votes from the vote denominator and counting only votes cast for or against. That alters the mechanics used to determine whether proposals pass and is an important governance change for shareholders to note when evaluating or participating in future votes.